▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / PMHS

PMHS — Polomar Health Services, Inc.

—
OTC · Health Care · Pharmaceuticals · CIK 1265521 ·
Last close
$0.15
Market Cap
$4.56M
52W High
$0.49
52W Low
$0.07
ADV30
864
Next earnings
—
Polomar Health Services, Inc. operates as a retail compounding pharmacy. The company owns SlimRx, a weight loss focused online platform connects patients with licensed physicians to prescribe weight loss medications, such as semaglutide compounded with vitamin B-12 and/or metformin; and intends to launch PoloMeds for diabetes medications, including metformin compounds, sulfonylureas, and insulin, as well as compounded erectile dysfunction medications inhalable sildenafil. It also includes dermatological formulations for the treatment of acne, alopecia areata, basal cell carcinoma, Becker's nevus, vitiligo, and other common skin conditions. In addition, it provides prescription fulfillment services for third party web based tele-health platforms. The company is based in Los Angeles, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2025 632,057 448,763 -8,942,714 -8,988,912 390,043 132,150 1,612,372
Sep 2025 6,163 4,323 -628,808 -649,775 9,269,726 38,854 1,503,130
Jun 2025 5,470 3,832 -563,333 -605,563 9,432,865 4,678 1,036,921
Mar 2025 4,542 3,182 -415,408 -456,855 9,808,644 129,331 1,666,368

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-901,011
Investing CF
$0
Financing CF
$923,663
CapEx
$-10,661
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.07
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-4,623,356
Inventory
$158,810
Receivables
$0
ST Investments
—
EBIT TTM
$-2,296,661
Pretax Income TTM
$-2,430,982
Interest Exp TTM
$116,804
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$648,231
EBITDA
$-776,936
Free Cash Flow
$3,629,784
Enterprise Value
$4,988,337
Total Cash
$132,150
Total Debt
$912,524
Shares Out
30,385,726
Trailing EPS
$-0.39
Book Value
$0.28
ROE
-290.1%
ROA
-127.5%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 648,231 -10,550,264 -10,701,105 390,043 1,612,372 — -395,995
Dec 2024 58,824 -1,299,496 -1,341,333 9,951,773 1,352,642 — -1,019,787
Dec 2023 41,844 -440,832 -587,997 107,099 151,635 — -534,307
Dec 2022 34,526 -181,453 -181,124 261,484 74,715 — -40,934

Peers — same industry

TickerNameMarket CapLastDaily %
GELS Gelteq Ltd $4.52M $0.42 —
ENSC Ensysce Biosciences, Inc. $4.52M $0.31 —
MTNB Matinas BioPharma Holdings, Inc. $4.66M $0.73 —
ALZN Alzamend Neuro, Inc. $4.38M $1.15 —
ACUT Accustem Sciences Inc. $4.34M $0.27 —

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →